RT Journal Article
SR Electronic
T1 Nivolumab-induced exocrine pancreatic insufficiency
JF Frontline Gastroenterology
JO Frontline Gastroenterol
FD BMJ Publishing Group Ltd
SP 167
OP 170
DO 10.1136/flgastro-2021-102013
VO 14
IS 2
A1 Anna Jones
A1 Kay Rodgers
A1 Debbie Jeffrey
A1 Waqas I Ali
A1 HJN Andreyev
YR 2023
UL http://fg.bmj.com/content/14/2/167.abstract
AB Immune checkpoint inhibition is the standard-of-care for many advanced cancers. Side effects of therapy may prevent optimal treatment of the cancer. Management of side effects is dominated by recommendations derived from oncological, not gastroenterological practice. We report a patient who developed pancreatic insufficiency during checkpoint inhibitor therapy with a programmed cell death receptor 1 inhibitor, nivolumab, which if not diagnosed would have prevented ongoing treatment. This is a problem which affects approximately 1 in 100 patients treated with this agent but is rarely recognised. Gastroenterologists need to be aware of the spectrum of gastrointestinal disorders which occur after immunotherapy to treat cancer.